Top 10 Early Stage Investors: Cancer Therapeutics & Diagnostics
| Rank | Investor Name |
|---|---|
| 1 | Even One Ventures |
| 2 | dRx Capital |
| 3 | F-Prime Capital |
| 4 | Camden Partners |
| 5 | Eli Lilly and Company |
| 6 | Cormorant Asset Management |
| 7 | Astellas Venture Management |
| 8 | Omega Funds |
| 9 | Oncology Ventures |
| 10 | New Enterprise Associates |
Early stage activity in this category is led by institutional venture franchises and category specialists. Oncology remains the deepest therapeutic category, driven by precision medicine and strategic pharma demand. For a company raising a priced early round, this list identifies the firms with the most active recent presence in the category.
The CapitalDart directory identifies the right person to contact at each of these firms, with their individual investment criteria.
Rankings reflect investment activity from January 2025 through July 2026 in US and Canada companies, based on transactions matched to the CapitalDart directory. Seed and Early Stage rank by participation, Later Stage by rounds led, Private Equity by control and buyout activity. Updated periodically.